Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8161 to 8175 of 8887 results

  1. Interferon beta-1b, interferon beta-1a and glatiramer acetate for the treatment of single demyelinating event with clinically isolated syndrome [ID109]

    Discontinued Reference number: GID-TAG415

    Technology appraisal guidance
    Discontinued

  2. Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]

    Discontinued Reference number: GID-TAG440

    Technology appraisal guidance
    Discontinued

  3. Hepatitis C (genotype 1, chronic) - faldaprevir [ID670]

    Discontinued Reference number: GID-TAG456

    Technology appraisal guidance
    Discontinued

  4. Clostridium difficile associated diarrhoea - tolevamer [ID378]

    Discontinued Reference number: GID-TAG389

    Technology appraisal guidance
    Discontinued

  5. Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) [ID622]

    Discontinued Reference number: GID-TAG360

    Technology appraisal guidance
    Discontinued

  6. T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]

    Discontinued Reference number: GID-TAG433

    Technology appraisal guidance
    Discontinued

  7. Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]

    Discontinued Reference number: GID-TAG332

    Technology appraisal guidance
    Discontinued

  8. Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]

    Discontinued Reference number: GID-TAG435

    Technology appraisal guidance
    Discontinued

  9. Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407]

    Discontinued Reference number: GID-TAG425

    Technology appraisal guidance
    Discontinued

  10. Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]

    Discontinued Reference number: GID-TAG424

    Technology appraisal guidance
    Discontinued

  11. Lung cancer (non-small cell) - afatinib [ID357]

    Discontinued Reference number: GID-TAG422

    Technology appraisal guidance
    Discontinued

  12. Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]

    Discontinued Reference number: GID-TA10722

    Technology appraisal guidance
    Discontinued

  13. Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]

    In development Reference number: GID-TA11406 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Glaucoma - lerdelimumab (CAT-152) [ID383]

    Discontinued Reference number: GID-TAG381

    Technology appraisal guidance
    Discontinued

  15. Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]

    Discontinued Reference number: GID-TA11411

    Technology appraisal guidance
    Discontinued